Antiphospholipid Syndrome: Statement Analysis
Direct Answer to Each Statement
b) Anticardiolipin antibodies are typically elevated - TRUE
f) Women with APS are at risk of developing pre-eclampsia - TRUE
e) Positive LA indicates a worse prognosis - TRUE
c) It is found in patients with scleroderma - TRUE (but less commonly than in SLE)
a) Arterial thromboses are more common - FALSE
d) Characteristic purpuric rash - FALSE
Detailed Analysis
Statement b: Anticardiolipin Antibodies Are Typically Elevated - TRUE
Anticardiolipin antibodies (aCL) are one of the three cornerstone laboratory criteria for APS diagnosis. The 2020 ACR guidelines define positive aPL as persistent moderate-to-high titer aCL (≥40 units or ≥99th percentile) on two occasions at least 12 weeks apart 1. Among patients with SLE, the prevalence of anticardiolipin antibodies ranges from 12% to 30% 2. In general, anticardiolipin antibodies occur approximately five times more often than lupus anticoagulant in patients with antiphospholipid syndrome 2.
Statement f: Women with APS Are at Risk of Pre-eclampsia - TRUE
Women with APS face significantly elevated risk of pre-eclampsia, with rates approximating 10-20% in APS pregnancies. The 2017 EULAR guidelines specifically state that women with SLE at risk of pre-eclampsia (especially those with lupus nephritis or positive aPL) should receive low-dose aspirin 3. The high-risk aPL profile correlates with increased risk of pre-eclampsia (OR 2.3) 3. The 2020 ACR guidelines emphasize that presence of aPL regardless of clinical history is considered a risk factor for development of preeclampsia 4.
Statement e: Positive Lupus Anticoagulant Indicates Worse Prognosis - TRUE
Among all antiphospholipid antibodies, lupus anticoagulant (LA) conveys the greatest risk for adverse outcomes. The PROMISSE study demonstrated that the relative risk for adverse pregnancy outcome with LA was 12.15 (95% CI 2.92–50.54, P = 0.0006) 4. The 2017 EULAR guidelines specify that high-risk aPL profile (including LA and multiple aPL positivity) correlates with increased risk of maternal vascular thrombotic events during pregnancy (OR 12.1), pre-eclampsia (OR 2.3), and APS-related pregnancy morbidity (OR 9.2) 3.
Statement c: Found in Patients with Scleroderma - TRUE (with caveats)
While the evidence provided focuses primarily on SLE and primary APS, antiphospholipid antibodies can occur in various autoimmune disorders. The syndrome can occur within the context of several diseases, mainly autoimmune disorders, termed secondary antiphospholipid syndrome 2. However, the association is strongest with SLE, where prevalence ranges from 12-34% for various aPL 2. The connection to scleroderma specifically is less well-documented in the provided guidelines but is recognized in clinical practice as part of the broader spectrum of autoimmune disease associations.
Statement a: Arterial Thromboses Are More Common - FALSE
Venous thrombosis is more common than arterial thrombosis in APS. While APS is characterized by both arterial and venous thrombosis 5, 6, the literature does not support arterial events being more frequent. The syndrome is described as "the most common cause of acquired thrombophilia, associated with either venous or arterial thrombosis or both" 2, but venous events predominate in most series. Arterial thrombosis represents "a lesser clinical expression" that is "less studied" 7.
Statement d: Characteristic Purpuric Rash - FALSE
There is no characteristic purpuric rash specific to APS. While cutaneous manifestations can occur in APS, they are varied and non-specific. Reported skin findings include livedo reticularis, necrotizing vasculitis, livedoid vasculitis, thrombophlebitis, cutaneous ulceration and necrosis, erythematous macules, purpura, ecchymoses, painful skin nodules, and subungual splinter hemorrhages 8. Purpura may occur but is not characteristic or diagnostic. The most frequent histopathologic feature is noninflammatory vascular thrombosis 8.
Clinical Pearls
- Triple-positive patients (LA, aCL, and anti-β2GPI all positive) represent the highest-risk group and require aggressive management with vitamin K antagonists 9
- Laboratory criteria require persistence: Two positive tests at least 12 weeks apart are mandatory for diagnosis 1
- Moderate-to-high titers matter: Thresholds of ≥40 units define clinically significant antibody levels 1
- IgG isotypes carry higher risk than IgM, though both are included in classification criteria